Marco Donia: We discuss a combined transcriptional and phenotype signature, NeoTCRPBL
Marco Donia, Associate Professor at National Center for Cancer Immune Therapy, Denmark, shared on LinkedIn:
Harnessing neoantigen-specific T cells for precision cancer immunotherapy
Nature Reviews Clinical Oncology, Jan 2024, free access link.
(Commentary from Inge Marie Svane and me about “Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers”, by Rami Yoseph (Yossef) et al., Cancer Cell, December 2023, original article free access)
Several novel personalized therapies focus on targeting neoantigens. Such strategies require the identification of suitable vaccine neoepitopes or neoantigen-specific T cell receptor (TCR) clonotypes.
Herein, we discuss a recently published report that describes a combined transcriptional and phenotype signature, NeoTCRPBL, that enables the minimally invasive identification of rare neoantigen-specific TCRs from peripheral blood that might enable more effective T cell-based therapies against cancer.”
Source: Marco Donia/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023